HLS 18RS-974 ENGROSSED

2018 Regular Session

HOUSE BILL NO. 579

1

BY REPRESENTATIVE JAMES

PHARMACISTS: Provides relative to the authorization for therapeutic use of marijuana

AN ACT

2 To amend and reenact R.S. 40:1046(A) and (G) and R.S. 40:1046(A) and (G) as amended 3 and reenacted by Section 2 of Act No. 96 of the 2016 Regular Session of the 4 Legislature of Louisiana, relative to the authorization of marijuana for therapeutic 5 use; to provide for the duties and authorization of the Louisiana State Board of 6 Medical Examiners and the Louisiana Board of Pharmacy with respect to the 7 therapeutic use of marijuana; to provide for definitions; and to provide for related 8 matters. 9 Be it enacted by the Legislature of Louisiana: 10 Section 1. R.S. 40:1046(A) and (G) are hereby amended and and reenacted to read 11 as follows: 12 §1046. Recommendation of marijuana for therapeutic use; rules and regulations; 13 Louisiana Board of Pharmacy and the adoption of rules and regulations 14 relating to the dispensing of recommended marijuana for therapeutic use; the 15 Department of Agriculture and Forestry and the licensure of a production 16 facility 17 A.(1) Notwithstanding any other provision of this Part, a physician licensed 18 by and in good standing with the Louisiana State Board of Medical Examiners to 19 practice medicine in this state and who is domiciled in this state may recommend, 20 in any form as permitted by the rules and regulations of the Louisiana Board of

1 Pharmacy except for inhalation, and raw or crude marijuana, tetrahydrocannabinols, 2 or a chemical derivative of tetrahydrocannabinols marijuana or marijuana 3 preparations for therapeutic use by patients clinically diagnosed as suffering from a 4 debilitating medical condition. (2)(a) For purposes of this Subsection, "debilitating medical condition" 5 6 means cancer, glaucoma, positive status for human immunodeficiency virus, 7 acquired immune deficiency syndrome, cachexia or wasting syndrome, seizure 8 disorders, epilepsy, spasticity, severe muscle spasms, intractable pain, Crohn's 9 disease, muscular dystrophy, or multiple sclerosis, or post-traumatic stress disorder. 10 (b) Intractable pain means a pain state in which the cause of the pain cannot 11 be removed or otherwise treated with the consent of the patient and which, in the 12 generally accepted course of medical practice, no relief or cure of the cause of the 13 pain is possible, or none has been found after reasonable efforts. It is pain so chronic 14 and severe as to otherwise warrant an opiate prescription. 15 (c) The Louisiana State Board of Medical Examiners shall adopt rules 16 relating to the approval or denial of additional qualifying conditions. 17 (d) If the United States Food and Drug Administration approves the use of 18 medical marijuana in the same form provided for in this Part for any debilitating 19 medical condition specifically identified in this Paragraph, that medical condition 20 shall no longer be covered by the provisions of this Part. 21 (e) If the United States Food and Drug Administration approves the use 22 of medical marijuana in a form or derivative different than provided for in this Part 23 for any debilitating medical condition specifically identified in this Paragraph, the 24 disease state shall remain covered by the provisions of this Part. The patient shall first be treated by the approved form or derivative of medical marijuana through 25 26 utilization of step therapy or fail first protocols. If, after use of the United States 27 Food and Drug Administration approved form or derivative of medical marijuana, 28 the physician determines that the preferred treatment required under step therapy or

fail first protocol has been ineffective in the treatment of the patient's debilitating

28

1	medical condition, he may recommend the form of medical marijuana provided for
2	in this Part for use by the patient as medically necessary.
3	(3) For purposes of this Part, "recommend" or "recommended" means an
4	order from a physician domiciled in Louisiana and licensed and in good standing
5	with the Louisiana State Board of Medical Examiners and authorized by the board
6	to recommend medical marijuana that is patient-specific and disease-specific in
7	accordance with Paragraph (2) of this Subsection, and is communicated by any
8	means allowed by the Louisiana Board of Pharmacy to a Louisiana-licensed
9	pharmacist in a Louisiana-permitted dispensing pharmacy as described in Subsection
10	G of this Section, and is preserved on file as required by Louisiana law or federal law
11	regarding medical marijuana.
12	(4) Physicians shall may recommend use of medical marijuana for treatment
13	of debilitating medical conditions in accordance with rules and regulations
14	promulgated by the Louisiana State Board of Medical Examiners.
15	(5) Any member of the public may petition the Louisiana State Board of
16	Medical Examiners for the addition of serious medical conditions and medical
17	marijuana treatment options.
18	(6) The Louisiana State Board of Medical Examiners shall submit to the
19	Senate and House committees on health and welfare on an annual basis not less than
20	sixty days prior to the beginning of the regular session of the legislature a report as
21	to any additional diseases or medical conditions that should will be added to the list
22	of eligible diseases and conditions for recommendation <u>pursuant to review of public</u>
23	notice and comment.
24	* * *
25	G.(1) The Louisiana Board of Pharmacy shall develop an annual,
26	nontransferable specialty license for a pharmacy to dispense recommended
27	marijuana for therapeutic use and shall limit the number of such licenses granted in

the state to no more than ten licensees. The Louisiana Board of Pharmacy shall

2	pharmacies in Louisiana.
3	(2) Pharmacists licensed pursuant to this Section may dispense marijuana
4	preparations and marijuana paraphernalia to patients enrolled in the state-sponsored
5	medical marijuana program in Louisiana, their caregivers, and minor patients'
6	domiciliary parents.
7	(3) Licensed dispensing pharmacies may not dispense raw or crude
8	marijuana to a patient or a parent or caregiver of a patient.
9	(4) No patient enrolled in the state-sponsored medical marijuana program
10	may smoke marijuana or marijuana preparations. A qualifying patient may vaporize
11	marijuana preparations.
12	(5)(a) For the purposes of this Subsection, "marijuana paraphernalia" means
13	objects used, intended for use, or designated for use in preparing, storing, ingesting,
14	vaporizing, or otherwise introducing medical marijuana into the human body. The
15	term does not include objects meant for smoking marijuana.
16	(b) For the purposes of this Subsection, "marijuana preparations" means any
17	form authorized by and consistent with the rules adopted by the Louisiana Board of
18	Pharmacy.
19	(c) For the purposes of this Subsection, "vaporize" means heating below the
20	point of combustion.
21	* * *
22	Section 2. R.S. 40:1046(A) and (G) as amended and reenacted by Section 2 of Act
23	No. 96 of the 2016 Regular Session of the Legislature of Louisiana are hereby amended and
24	reenacted to read as follows:
25	Section 2. R.S. 40:1046 is hereby amended and reenacted to read as follows:
26	§1046. Prescription of marijuana for therapeutic use; rules and regulations;
27	Louisiana Board of Pharmacy and the adoption of rules and
28	regulations relating to the dispensing of prescribed marijuana for

develop rules and regulations regarding the geographical locations of dispensing

therapeutic use; the Department of Agriculture and Forestry and the

2 licensure of a production facility 3 A.(1) Notwithstanding any other provision of this Part, a physician 4 licensed by and in good standing with the Louisiana State Board of 5 Medical Examiners to practice medicine in this state and who is domiciled 6 in this state may prescribe, in any form as permitted by the rules and 7 regulations of the Louisiana Board of Pharmacy except for inhalation, and 8 raw or crude marijuana, tetrahydrocannabinols, or a chemical derivative of 9 tetrahydrocannabinols marijuana or marijuana preparations for 10 therapeutic use by patients clinically diagnosed as suffering from a 11 debilitating medical condition glaucoma, symptoms resulting from the 12 administration of chemotherapy cancer treatment, and spastic quadriplegia 13 in accordance with rules and regulations promulgated by the Louisiana State 14 Board of Medical Examiners. The Louisiana State Board of Medical 15 Examiners shall submit to the Senate and House committees on health and 16 welfare on an annual basis not less than sixty days prior to the beginning of 17 the regular session of the legislature a report as to any additional diseases or 18 medical conditions that should be added to the list of eligible diseases and 19 conditions for prescription. 20 (2)(a) For purposes of this Subsection, "debilitating medical 21 condition" means cancer, glaucoma, positive status for human 22 immunodeficiency virus, acquired immune deficiency syndrome, 23 cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, 24 severe muscle spasms, intractable pain, Crohn's disease, muscular 25 dystrophy, or multiple sclerosis, or post-traumatic stress disorder. 26 (b) Intractable pain means a pain state in which the cause of the 27 pain cannot be removed or otherwise treated with the consent of the 28 patient and which, in the generally accepted course of medical practice, 29 no relief or cure of the cause of the pain is possible, or none has been

1	found after reasonable efforts. It is pain so chronic and severe as to
2	otherwise warrant an opiate prescription.
3	(c) The Louisiana State Board of Medical Examiners shall adopt
4	rules relating to the approval or denial of additional qualifying
5	conditions.
6	(b) (d) If the United States Food and Drug Administration
7	approves the use of medical marijuana in the same form provided for in
8	this Part for any debilitating medical condition specifically identified in
9	this Paragraph, that medical condition shall no longer be covered by the
10	provisions of this Part.
11	(c) (e) If the United States Food and Drug Administration
12	approves the use of medical marijuana in a form or derivative different
13	than provided for in this Part for any debilitating medical condition
14	specifically identified in this Paragraph, the disease state shall remain
15	covered by the provisions of this Part. The patient shall first be treated
16	by the approved form or derivative of medical marijuana through
17	utilization of step therapy or fail first protocols. If, after use of the
18	United States Food and Drug Administration approved form or
19	derivative of medical marijuana, the physician determines that the
20	preferred treatment required under step therapy or fail first protocol
21	has been ineffective in the treatment of the patient's debilitating medical
22	condition, he may prescribe the form of medical marijuana provided for
23	in this Part for use by the patient as medically necessary.
24	(3) For purposes of this Part, "prescribe" or "prescription"
25	means an order from a physician domiciled in Louisiana and licensed
26	and in good standing with the Louisiana Board of Medical Examiners
27	and authorized by the board to prescribe medical marijuana that is
28	patient-specific and disease-specific in accordance with Paragraph (2) of
29	this Subsection, and is communicated by any means allowed by the

1	Louisiana Board of Pharmacy to a Louisiana-licensed pharmacist in a
2	Louisiana-permitted dispensing pharmacy as described in Subsection G
3	of this Section, and is preserved on file as required by Louisiana law or
4	federal law regarding medical marijuana.
5	(4) Physicians shall may prescribe the use of medical marijuana
6	for treatment of debilitating medical conditions in accordance with rules
7	and regulations promulgated by the Louisiana State Board of Medical
8	Examiners.
9	(5) Any member of the public may petition the Louisiana State
10	Board of Medical Examiners for the addition of serious medical
11	conditions and medical marijuana treatment options.
12	(5) (6) The Louisiana State Board of Medical Examiners shall
13	submit to the Senate and House committees on health and welfare on an
14	annual basis not less than sixty days prior to the beginning of the regular
15	session of the legislature a report as to any additional diseases or medical
16	conditions that should will be added to the list of eligible diseases and
17	conditions for recommendation pursuant to review of public notice and
18	comment.
19	* * *
20	HG.(1) The Louisiana Board of Pharmacy shall develop an annual,
21	nontransferable specialty license for a pharmacy to dispense prescribed
22	marijuana for therapeutic use and shall limit the number of such licenses
23	granted in the state to no more than ten licensees. The Louisiana Board of
24	Pharmacy shall develop rules and regulations regarding the geographical
25	locations of dispensing pharmacies in Louisiana.
26	(2) Pharmacists licensed pursuant to this Section may dispense
27	marijuana preparations and marijuana paraphernalia to patients
28	enrolled in the state-sponsored medical marijuana program in
29	Louisiana, their caregivers, and minor patients' domiciliary parents.

1	(3) Licensed dispensing pharmacies may not dispense raw or
2	crude marijuana a patient or a parent or caregiver of a patient.
3	(4) No patient enrolled in the state-sponsored medical marijuana
4	program may smoke marijuana or marijuana preparations. A qualifying
5	patient may vaporize marijuana preparations.
6	(5)(a) For the purposes of this Subsection, "marijuana
7	paraphernalia" means objects used, intended for use, or designated for
8	use in preparing, storing, ingesting, vaporizing, or otherwise introducing
9	medical marijuana into the human body. The term does not include
10	objects meant for smoking marijuana.
11	(b) For the purposes of this Subsection, "marijuana
12	preparations" means any form authorized by and consistent with the
13	rules adopted by the Louisiana Board of Pharmacy.
14	(c) For the purposes of this Subsection, "vaporize" means
15	heating below the point of combustion.
16	* * *

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HB 579 Engrossed

2018 Regular Session

James

Abstract: Provides relative to the conditions for which medical marijuana may be recommended or prescribed.

Recommendation of Medical Marijuana

<u>Present law</u> authorizes physicians who are domiciled in La. and licensed by and in good standing with the La. State Board of Medical Examiners to <u>recommend</u> tetrahydrocannabinols (commonly referred to as "medical marijuana"), or chemical derivatives thereof, for therapeutic use by patients clinically diagnosed as suffering from a debilitating medical condition. Defines "debilitating medical condition" to mean cancer, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, Crohn's disease, muscular dystrophy, or multiple sclerosis.

<u>Proposed law</u> revises <u>present law</u> to authorize physicians who are domiciled in La. and licensed by and in good standing with the La. State Board of Medical Examiners to recommend marijuana or marijuana preparations for therapeutic use by patients clinically

Page 8 of 11

diagnosed as suffering from a debilitating medical condition. Adds the following to the set of conditions for which medical marijuana may be recommended:

- (1) Glaucoma.
- (2) Severe muscle spasms.
- (3) Intractable pain.
- (4) Post-traumatic stress disorder.

<u>Proposed law</u> defines "intractable pain" as a pain state in which the cause of the pain cannot be removed or otherwise treated with the consent of the patient and which, in the generally accepted course of medical practice, no relief or cure of the cause of the pain is possible, or none has been found after reasonable efforts. Provides further that intractable pain is pain so chronic and severe as to otherwise warrant an opiate prescription.

<u>Proposed law</u> provides that any member of the public may petition the La. State Board of Medical Examiners for the addition of serious medical conditions and medical marijuana treatment options.

<u>Present law</u> requires the La. Board of Pharmacy to develop an annual, nontransferable specialty license for a pharmacy to dispense recommended marijuana for therapeutic use. Provides that the number of such licenses shall be no more than ten. <u>Proposed law</u> retains <u>present law</u> and authorizes pharmacists licensed pursuant to <u>present law</u> to dispense marijuana preparations and marijuana paraphernalia to patients, their caregivers, and minor patients' domiciliary parents.

<u>Proposed law</u> stipulates that licensed marijuana dispensing pharmacies may not dispense raw or crude marijuana a patient or a parent or caregiver of a patient.

<u>Proposed law</u> prohibits smoking but allows vaporizing of marijuana or marijuana preparations.

<u>Proposed law</u> establishes the following defined terms and corresponding definitions for purposes of proposed law:

- (1) "Marijuana paraphernalia" means objects used, intended for use, or designated for use in preparing, storing, ingesting, vaporizing, or otherwise introducing medical marijuana into the human body. The term does not include objects meant for smoking marijuana.
- (2) "Marijuana preparations" means any form authorized by and consistent with the rules adopted by the La. Board of Pharmacy.
- (3) "Vaporize" means heating below the point of combustion.

Prescription of Medical Marijuana

<u>Present law</u> authorizes physicians who are domiciled in La. and licensed by and in good standing with the La. State Board of Medical Examiners to <u>prescribe</u>, rather than recommend, medical marijuana for therapeutic use by patients clinically diagnosed as suffering from a debilitating medical condition if and when the U.S. Drug Enforcement Administration reclassifies marijuana from a Schedule I drug to a Schedule II drug, thereby allowing the drug to be legally prescribed. Defines "debilitating medical condition" to mean cancer, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, cachexia or wasting syndrome, seizure disorders, epilepsy, spasticity, Crohn's disease, muscular dystrophy, or multiple sclerosis.

<u>Proposed law</u> revises <u>present law</u> to authorize physicians who are domiciled in La. and licensed by and in good standing with the La. State Board of Medical Examiners to prescribe marijuana or marijuana preparations for therapeutic use by patients clinically diagnosed as suffering from a debilitating medical condition. Adds the following to the set of conditions for which medical marijuana may be prescribed:

- (1) Glaucoma.
- (2) Severe muscle spasms.
- (3) Intractable pain.
- (4) Post-traumatic stress disorder.

<u>Proposed law</u> defines "intractable pain" as a pain state in which the cause of the pain cannot be removed or otherwise treated with the consent of the patient and which, in the generally accepted course of medical practice, no relief or cure of the cause of the pain is possible, or none has been found after reasonable efforts. Provides further that intractable pain is pain so chronic and severe as to otherwise warrant an opiate prescription.

<u>Proposed law</u> provides that any member of the public may petition the La. State Board of Medical Examiners for the addition of serious medical conditions and medical marijuana treatment options.

<u>Present law</u> requires the La. Board of Pharmacy to develop an annual, nontransferable specialty license for a pharmacy to dispense prescribed marijuana for therapeutic use. Provides that the number of such licenses shall be no more than ten. <u>Proposed law</u> retains <u>present law</u> and authorizes pharmacists licensed pursuant to <u>present law</u> to dispense marijuana preparations and marijuana paraphernalia to patients, their caregivers, and minor patients' domiciliary parents.

<u>Proposed law</u> stipulates that licensed marijuana dispensing pharmacies may not dispense raw or crude marijuana a patient or a parent or caregiver of a patient.

<u>Proposed law</u> prohibits smoking but allows vaporizing of marijuana or marijuana preparations.

<u>Proposed law</u> establishes the following defined terms and corresponding definitions for purposes of proposed law:

- (1) "Marijuana paraphernalia" means objects used, intended for use, or designated for use in preparing, storing, ingesting, vaporizing, or otherwise introducing medical marijuana into the human body. The term does not include objects meant for smoking marijuana.
- (2) "Marijuana preparations" means any form authorized by and consistent with the rules adopted by the La. Board of Pharmacy.
- (3) "Vaporize" means heating below the point of combustion.

(Amends R.S. 40:1046(A) and (G) and R.S. 40:1046(A) and (G) as amended and reenacted by Section 2 of Act No. 96 of the 2016 R.S.)

Summary of Amendments Adopted by House

The Committee Amendments Proposed by <u>House Committee on Health and Welfare</u> to the original bill:

- 1. Revise <u>proposed law</u> defining "marijuana preparations" to provide that such preparations can be any form authorized by and consistent with the rules adopted by the La. Board of Pharmacy.
- 2. Amend <u>present law</u> relative to prescription of medical marijuana to reflect amendments <u>proposed law</u> makes in <u>present law</u> relative to recommendation of medical marijuana.
- 3. Make technical changes.